Italfarmaco SpA and Iktos have announced a collaboration to develop next-generation HDAC inhibitors for non-oncological diseases, leveraging Iktos’s AI-driven Makya and Spaya platforms for innovative molecule design and synthesis. This partnership aims to accelerate drug discovery and optimize resource use, with a focus on diseases affecting the central nervous system.
“We are thrilled to announce our collaboration with ITF“, stated Dr. Quentin Perron, Co-founder and CSO of Iktos. “Our commitment at Iktos lies in advancing innovative technologies that augment the likelihood of success in small molecule discovery. Our ultimate goal is to accelerate drug discovery through the application of AI, thanks to our robust algorithmic technology and our wealth of expertise gained through numerous successful collaborations.”
Discover more here.